Trastuzumab deruxtecan (DS-8201a) is a HER2-targeting antibody-drug conjugate, with a high drug-to-antibody ratio (DAR) of 7 to 8. The high DAR could lead to more potent antitumor activity in cancers with low-HER2 expression. 43 patients were evaluable in this trial, and around 27% of patients had received 5 or more prior anticancer therapies. HER2 expression was 3+ on immunohistochemistry in majority of patients (80%).The confirmed objective response rate (ORR) was 44.2% and the disease control rate (DCR) was 79.1%. The medial progression free survival was 5.8 months. Overall, Trastuzumab deruxtecan (DS-8201a) demonstrated a clinically meaningful benefit with a manageable toxicity profile.
Source : Journal of Clinical Oncology 2018 36:4_suppl, 118-118